Largest study on infant-type hemispheric glioma reports factors to guide treatment approaches

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clinician-scientists at St. Jude Children’s Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Ronald McDonald House New York announced the completion of its renovation of the Community Floor, a reimagined space designed to enhance the everyday experience of children and families staying at the House while their children receive treatment for serious illnesses. The project, which has transformed dining, kitchen, play, and program areas on the second floor of the House at 405 East 73rd Street, creates spaces where families can share meals, children can play and learn, and caregivers can find opportunities for connection, respite, and support.
FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login